Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / ARDX - Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap Says Analyst | Benzinga

ARDX - Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap Says Analyst | Benzinga

Ardelyx Inc.

Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing:

  • Ibsrela in year two of its launch (FY23 guidance $77 million at midpoint) in irritable bowel syndrome with predominant constipation (IBS-C).
  • Newly approved Xphozah was launched in hyperphosphatemia this quarter after a successful post-CRL appeal process.

The analysts Ryan Deschner and Steven Seedhouse initiate with a Strong Buy rating and Full story available on Benzinga.com
Stock Information
Company Name: Ardelyx Inc.
Stock Symbol: ARDX
Market: NASDAQ
Website: ardelyx.com
Menu
ARDX ARDX Quote ARDX Short ARDX News ARDX Articles ARDX Message Board
Get ARDX Alerts

News, Short Squeeze, Breakout and More Instantly...